CD274 and acute kidney injury: Renal irAEs are rare, with an estimated incidence of 2% with anti-PD-1/PD-L1 mAbs and 5% with combination therapy in a review of published phase 2 and 3 trials, but more recent studies have suggested that the incidence of AKI is higher than that initially reported [5, 6].